The Selectivity Challenge
Many biologics struggle to distinguish diseased tissue from healthy tissue, limiting their safety and efficacy potential.
- Disease targets can closely resemble healthy targets.
- Subtle structural features can control binding.
- Protein interactions are dynamic, not static.
- The design space is too large to test experimentally.
9Bio’s Approach
9Bio designs biologics to act more precisely where they are needed, aiming to improve both safety and efficacy.
- Structure-guided design: We model protein structure to understand how biologics bind and how that binding can be engineered.
- Dynamic interaction modeling: We study how proteins behave across changing biological conditions, not just in a single static state.
- Large-scale design exploration: We screen vast numbers of protein variants digitally to find rare candidates with the right performance profile.
- The result: A more predictive path to disease-selective biologics, with large-scale digital exploration used to identify the best candidates before lab testing.
